Share on LinkedInShare on LinkedIn

ARTICLE · 04 NOVEMBER 2010

Myriad Genetics Ruling - Human Gene Patents Invalidated in US District Court

Myriad Genetics patents on two genes linked to breast and ovarian cancer (BRCA1 and BRCA2,) have been struck down in a US District Court ruling – Judge Sweet stating that the patents "are directed to a law of nature and were therefore improperly granted" (Association for Molecular Biology et. al. Vs United States Patent and Trademark Office et. al.; "the Myriad decision"). This is a pivotal case for those operating in the biotech space and will shape the future of gene patenting and the developi

AustraliaIntellectual Property

Myriad Genetics patents on two genes linked to breast and ovarian cancer (BRCA1 and BRCA2,) have been struck down in a US District Court ruling – Judge Sweet stating that the patents "are directed to a law of nature and were therefore improperly granted" ( Association for Molecular Biology et. al. Vs United States Patent and Trademark Office et. al.; "the Myriad decision"). This is a pivotal case for those operating in the biotech space and will shape the future of gene patenting and the developing biotechnology industry.

A case was brought against Myriad Genetics last year in relation to a suite of patents covering genes linked to detection of breast and ovarian cancer. The American Civil Liberties Union (ACLU) attorneys acting for patients, pathologists, genetic researchers and other scientists, argued that gene patents suffocated research and competition. Myriad Genetics, it was argued, has a stronghold over use of these genes, which has consequently

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from